Status:
TERMINATED
Cytisine Compared to Combination NRT in Relapsed Smokers
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Conditions:
Smoking Cessation
Coronary Artery Disease
Eligibility:
All Genders
Phase:
NA
Brief Summary
Cigarette smoking causes cardiovascular disease (CVD) yet many smokers with CVD are unable to quit despite strong desire to do so. Within 90 days of discharge, about 30% of smokers have returned to da...
Detailed Description
Cigarette smoking is a causative factor in the development of coronary heart disease (CHD), and is the most dangerous form of tobacco use. Effective treatments for smoking cessation exist but relapse ...
Eligibility Criteria
Inclusion
- Patient is enrolled in UOHI's Quit Smoking Program;
- Patient has relapsed to daily smoking ≥10 cigarettes per day within 90 days of discharge from UOHI;
- Patient is currently smoking ≥10 cigarettes per day.
Exclusion
- Patient has used NRT, cytisine, varenicline, bupropion or a nicotine-containing vaping device within in the past 15 days;
- Patient is unavailable to come to UOHI for assessments;
- Patient is unable to provide informed consent;
- Patient is unable to comprehend the intervention instructions (in the opinion of qualified investigators)
Key Trial Info
Start Date :
March 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 7 2023
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT04286295
Start Date
March 14 2022
End Date
November 7 2023
Last Update
December 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Ottawa Heart Insitute - Prevention and Wellness Centre
Ottawa, Ontario, Canada, K1Y 4W7